Nootropic Agents - Pharmacology
Research News and Information

Sunday, November 22, 2009

Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

30 Aug 2009 Galantamine, a novel Alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nAChR) in the brain. We previously reported that galantamine potentiates the NMDA-induced currents in primary ... Read more...

Acute cognitive effects of donepezil in young, healthy volunteers.

30 Jul 2009 OBJECTIVE: The acute nootropic potential of donepezil in young healthy volunteers has not been adequately investigated mainly because in previous studies: (1) effects were assessed before peak-plasma concentration (Tmax) was reached; (2) only a few ... Read more...

The inhibitory avoidance test optimized for discovery of cognitive enhancers.

30 Jul 2009 In the present article, we describe a new protocol for the inhibitory avoidance test, with a dual purpose: (1) to provide a less variable and more reliable assessment of the efficacy of potential cognitive enhancers in antagonizing ... Read more...

Latest indexed articles for 'Nootropic Agents - Pharmacology'

These are the very latest articles for this heading:

• Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. 30 Aug 2009
• Acute cognitive effects of donepezil in young, healthy volunteers. 30 Jul 2009
• The inhibitory avoidance test optimized for discovery of cognitive enhancers. 30 Jul 2009
• The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. 30 Jul 2009
• Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. 30 Jul 2009
• Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice. 13 Jul 2009
• Recovery of cognitive dysfunction in a case of delayed encephalopathy of carbon monoxide poisoning after treatment with donepezil hydrochloride. 29 Jun 2009
• [Cytoprotective effect of neuropeptides on immunocompetent cells (in vitro study)] 29 Jun 2009
• Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. 30 May 2009
• Memory-enhancing drugs: a molecular perspective. 30 May 2009
• A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. 30 May 2009
• Cognitive-enhancing activity of loganin isolated from Cornus officinalis in scopolamine-induced amnesic mice. 25 May 2009
• Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. 19 May 2009
• Nelumbo nucifera semen extract improves memory in rats with scopolamine-induced amnesia through the induction of choline acetyltransferase expression. 18 May 2009
• Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. 12 May 2009
• The anti-amnesic effects of luteolin against amyloid beta(25-35) peptide-induced toxicity in mice involve the protection of neurovascular unit. 11 May 2009
• Timosaponin AIII, a saponin isolated from Anemarrhena asphodeloides, ameliorates learning and memory deficits in mice. 3 May 2009
• Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents. 29 Apr 2009
• Nootropic agents stimulate neurogenesis. Brain Cells, Inc.: WO2007104035. 29 Apr 2009
• Therapeutic targets for Alzheimer's disease. 29 Apr 2009

See a longer list of these articles.

Technical information about 'Nootropic Agents'

Definition: Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Registry Number: 0

Descriptor UI: D018697

Alternative terms: Nootropic Agents; Agents, Nootropic; Nootropics; Cognitive Enhancers; Enhancers, Cognitive; Nootropic Drugs; Drugs, Nootropic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.637;

Online Note: use PSYCHOTROPIC DRUGS to search NOOTROPIC DRUGS 1990-94

History Note: 95; NOOTRPIC DRUGS was see PSYCHOTROPIC DRUGS 1990-94

Technical Notes: CNS agents; from Greek nous, mind; GEN or unspecified: prefer specifics